Want to see AU:ATX full AI Analyst Report?
Top Page
Amplia Therapeutics
(Sydney:ATX)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.08
▼(-45.71% Downside)
Action:Reiterated
Date:10/17/26
The score is driven primarily by weak financial performance (revenue dropping to zero, continued losses, and worsening cash burn) and bearish technicals (price below all key moving averages with negative momentum). A solid equity cushion on the balance sheet provides some support, but valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Equity Cushion and Low Leverage
The substantial equity cushion and generally low leverage provide financial resilience relative to the company’s asset base. This structure may give Amplia more flexibility to fund development activities and absorb operating losses, although ongoing cash consumption remains an important constraint.
Negative Factors
Revenue Has Fallen to Zero
The collapse from prior revenue to zero demonstrates that the company currently lacks recurring commercial income to support its operations. This leaves financial performance dependent on development progress and future funding or licensing outcomes, making near-term business sustainability less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Equity Cushion and Low Leverage
The substantial equity cushion and generally low leverage provide financial resilience relative to the company’s asset base. This structure may give Amplia more flexibility to fund development activities and absorb operating losses, although ongoing cash consumption remains an important constraint.
Read all positive factors
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$40.04M
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth21.23%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume2,437,967
30 Day Avg. Volume1,012,163
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Amplia Therapeutics Business Overview & Revenue Model
Company Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor o...
Amplia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.78M | 4.45M | 1.19M | 1.98M |
| Gross Profit | -92.14K | 3.57M | 4.01M | 1.12M | 1.98M |
| EBITDA | -13.09M | -6.71M | -4.48M | -7.26M | -3.64M |
| Net Income | -7.71M | -6.57M | -4.50M | -6.24M | -3.64M |
Balance Sheet | |||||
| Total Assets | 41.44M | 22.94M | 14.85M | 18.68M | 24.48M |
| Cash, Cash Equivalents and Short-Term Investments | 27.85M | 10.86M | 3.39M | 9.26M | 14.61M |
| Total Debt | 341.11K | 13.89K | 1.59M | 2.27M | 2.10M |
| Total Liabilities | 1.97M | 1.91M | 3.43M | 2.85M | 2.64M |
| Stockholders Equity | 39.47M | 21.02M | 11.42M | 15.84M | 21.85M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -6.89M | -5.13M | -5.31M | -4.42M |
| Operating Cash Flow | -8.73M | -6.89M | -5.13M | -5.29M | -4.40M |
| Investing Cash Flow | -96.22K | -2.07K | -2.23K | -58.42K | -26.64K |
| Financing Cash Flow | 25.94M | 14.32M | -772.98K | -84.22K | 17.19M |
Amplia Therapeutics Technical Analysis
Negative
0.14
Price Trends
0.12
Negative
0.13
Negative
0.14
Negative
Market Momentum
-0.01
Positive
21.26
Positive
8.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.12, and above the 200-day MA of 0.14, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 21.26 is Positive, neither overbought nor oversold. The STOCH value of 8.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ATX.
Amplia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.36B | 118.10 | 6.03% | 0.80% | -68.00% | -86.31% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% | |
44 Neutral | AU$60.72M | -2.26 | -48.25% | ― | ― | -16.21% | |
43 Neutral | AU$47.39M | -12.17 | -63.60% | ― | ― | 29.55% | |
41 Neutral | AU$40.04M | -4.61 | -18.71% | ― | ― | 21.23% |
* Healthcare Sector Average
AU:ATX
Amplia Therapeutics
0.08
-0.05
-36.80%
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-18.92%
AU:NEU
Neuren Pharmaceuticals Limited
18.70
-2.54
-11.98%
AU:PAR
Paradigm Biopharmaceuticals
0.25
-0.18
-42.35%
AU:ATH
Alterity Therapeutics
0.24
-0.31
-56.36%
AU:ZLD
Zelira Therapeutics
0.50
0.19
61.29%
Amplia Therapeutics Corporate Events
Amplia Showcases FAK Inhibitor Progress at CG Drug and Device Conference
Oct 12, 2026
Amplia Therapeutics has released CEO Chris Burns’ presentation delivered at the Canaccord Genuity Drug and Device Conference 2026 in Noosa, highlighting progress across its clinical programs. The disclosure underscores the company’s ef...
Amplia Showcases FAK Oncology Pipeline at E&P Healthcare Conference
Sep 16, 2026
Amplia Therapeutics said Chief Executive Officer and Managing Director Dr Chris Burns is presenting today at the EP Healthcare Conference in Sydney, underscoring the company’s efforts to raise its profile among healthcare investors. The pres...
Amplia Wins Strong Shareholder Backing for AGM Resolutions and Capital Flexibility
Aug 28, 2026
Amplia Therapeutics said all resolutions at its 28 August annual general meeting were passed, including director elections, an additional 10% placement capacity, an increase in the non‑executive director fee pool and the issuance of zeroR...
Amplia Therapeutics Highlights Strong Pancreatic Cancer Data in AGM CEO Presentation
Aug 28, 2026
Amplia Therapeutics has released the CEO and Managing Director’s presentation for its Annual General Meeting for the year ended 31 March 2026. The presentation highlights the company’s focus on advancing narmafotinib (AMP945), a best-i...
Amplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push
Aug 6, 2026
Amplia Therapeutics has released a presentation for the Bioshares Biotech Summit in Queenstown, where Managing Director Dr Chris Burns will outline the company’s strategy of targeting pancreatic cancer and other fibrotic indications with its...
Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data
Jul 30, 2026
Amplia Therapeutics has highlighted new preclinical research on its lead FAK inhibitor narmafotinib in pancreatic cancer, now available on the bioRxiv server. The studies, led by Professor Paul Timpson at the Garvan Institute, explore how narmafot...
Amplia advances FAK inhibitor program with new trials, patent gains and board refresh
Jul 28, 2026
Amplia reported mature data from its ACCENT trial in metastatic pancreatic cancer showing that its FAK inhibitor narmafotinib, added to standard chemotherapy, delivered favourable safety and improved efficacy across key measures, including higher ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.